About Us
About Us
Our Stories
Academic Promotion
International Cooperation
Facilities
R&D-Pipeline
R&D
R&D Platform
Nuclear Medicine
Nuclear Medicine
Radioisotope
Radiopharmaceutical
Radiopharmaceuticals Production
News
Company News
Careers
Company Culture
Welfare
Contact Us
中
About Us
R&D-Pipeline
Nuclear Medicine
News
Careers
Contact Us
Company News
Jiangsu Sinotau Successfully Obtain the Radiation Safety License
…
2023-04-26
View details
Lantheus Announces Acquisition of Cerveau Technologies, Inc.，Which Is A Joint Venture of Sinotau
…
2023-02-09
View details
Adenosine Injection Is Approved for Marketing to Meet Clinical Needs for Myocardial Ischemia
…
2023-01-13
View details
Chinese Clinical Trials of PSMA-targeted RLT Drug for Metastatic Prostate Cancer Are Approved
…
2022-12-29
View details
Guangdong Sinotau Molecular Imaging Obtained the Radiopharmaceutical Production License
…
2022-10-20
View details
Early Diagnosis Is The Key to Early Know Alzheimer ——Florbetaben F18 Helps Early Diagnosis of AD
…
2022-09-30
View details
Completion of First Subject Enrollment in Phase III Clinical Trial of lutetium Lu 177 dotatate
…
2022-09-28
View details
First Chinese Marketing Application for Beta-amyloid PET Tracer Accepted by CDE
…
2022-07-11
View details
Guangdong Sinotau Molecular Imaging Technology Co., Ltd. Obtained the Radiation Safety License
…
2021-12-11
View details
Isotopia Molecular Imaging and Sinotau Pharmaceuticals Sign a Clinical Supply Agreement for 177Lu.
…
2021-11-04
View details
Sinotau Closes 320 Million RMB D+Financing, Co-investing by China Life Private Equity and Centurium
…
2021-10-21
View details
Sinotau Signs Agreement with HTA for New β-amyloid Imaging Agent
…
2017-11-02
View details
1
2
下一页 »
.jpg)
